

Parenteral Cytotoxic Chart

Patient Details

Forename

Surname

Protocol

PAZOPANIB

SA (m²)

Height (m)

Weight (kg)

DOB

Patient NO

Local No.

Course Name:

Pazopanib 800mg

Consultant

Ward

Type of line

No. of lumen:

Diagnosis

Prostatic carcinoma

NHS No

Monitoring	Acceptable Range		Date Due	Date of Test	Value	Checked
Height (m)						
Weight (kg)						
SA (m²)						
ALA TRANSAM 1 ULN	0.00	40.00	Day [1]			
BILIRUBIN 1.5ULN	0.00	31.50	Day [1]			
NEUTROPHILS > 1.0	1.00	15.00	Day [1]			
PLATELETS > 100	100.00	600.00	Day [1]			

Additional Prescribing Notes

Dose Modification
400mg and 200mg tablets are available- dose modifications should be made in 200mg increments
No dose adjustment is required in patients with CrCl>30mls/min
No dose adjustment is required in patients with mild hepatic impairment
For moderate hepatic impairment (defined as an elevation of Bilirubin >1.5 to 3 ULN) reduce dose by 200mg.
In severe hepatic impairment (defined as total Bilirubin >3 ULN regardless of ALT level) Pazopanib is contraindicated

Allocated by:

Confirmed by:

Authorised by:

Checked by: (Pharmacist)

Parenteral

Intrathecal

Oral

1

0

1

Date:

Date:

Date:

Date:

Chart Id.:

/ /

/ /

/ /

/ /

Patient Details

Forename	Surname		Protocol	PAZOPANIB					SA (m²)		
			Course Name	Pazopanib 800mg					Height (m)		
DOB	Patient NO	Local No.		NHS No						Weight (kg)	
Consultant		Ward		Diagnosis	Prostatic carcinoma						
Address											

Record drug allergies or sensitivities

				Time	Date													
Drug & dose	PAZOPANIB																	
Actual dose	800 mg		Duration	30 DAYS														
Route	PO		Start Date															
Frequency	DAILY		Start Day	1														
Quantity		Dispensed by																
Dispensed		Accuracy check																
Note																		

Allocated by:	Confirmed by:	Authorised by:	Checked by: (Pharmacist)	Chart Id.:
Date:	Date:	Date:	Date:	
/ /	/ /	/ /	/ /	